Connectomic Determinants of Subcallosal Cingulate Deep Brain Stimulation for Depression
OBJECTIVE: Subcallosal cingulate (SCC) deep brain stimulation (DBS) has shown promise for treatment-resistant depression. This study retrospectively evaluated a large curated SCC-DBS dataset to identify connectomic factors associated with sustained clinical improvement across patients, focusing on the white matter bundles consistently implicated in patient-specific connectome-based targeting. METHODS: A total of 131 patients (mean age=46.67 years, SD=9.79; 60.31% female) with treatment-resistant depression from three independent cohorts received bilateral SCC-DBS using site-specific targeting methods. Clinical improvements were assessed using the 17-item Hamilton Depression Rating Scale (HAM-D). Based on individual DBS settings, volumes of tissue activated were reconstructed, and voxel-wise stimulation mapping and normative fiber-wise analyses were performed to assess contributions of white matter bundles to therapeutic response. RESULTS: Responders (patients with ≥50% reduction in HAM-D score) exhibited a less variable spatial distribution of volumes of tissue activated than nonresponders. Probabilistic stimulation mapping identified a focal cluster associated with clinical improvement. Fiber-wise analyses showed that stimulation of predefined white matter tracts targeted by connectome-based SCC-DBS contributed to clinical efficacy. Notably, failure to activate the left cingulum bundle and medial uncinate fasciculus decreased the therapeutic effects of SCC-DBS. CONCLUSIONS: This study highlights the significance of stimulating critical white matter bundles for effective SCC-DBS. Available evidence supports the idea that precisely targeting the lateralized cingulum bundle and medial uncinate fasciculus is essential for sustained clinical improvement. These findings suggest potential advantages of connectome-based targeting for SCC-DBS over targeting based solely on anatomical landmarks or normative atlases, using a method that is precise, reliable, and scalable for future use in individual patients.
Authors
- Gavin J.B. Elias (ORCID: https://orcid.org/0000-0002-7495-550X)
- Brian Harris Kopell (ORCID: https://orcid.org/0000-0002-6955-4787)
- Jürgen Germann (ORCID: https://orcid.org/0000-0003-0995-8226)
- Martijn Figee (ORCID: https://orcid.org/0000-0003-3679-284X)
- Helen S. Mayberg (ORCID: https://orcid.org/0000-0002-1672-2716)
- Alexandre Boutet (ORCID: https://orcid.org/0000-0001-6942-5195)
- Sidney H. Kennedy (ORCID: https://orcid.org/0000-0001-5339-7185)
- Robert E. Gross (ORCID: https://orcid.org/0000-0003-1847-9227)
- Ha Neul Song (ORCID: https://orcid.org/0000-0001-7085-6988)
- Jungho Cha (ORCID: https://orcid.org/0000-0003-1189-2051)
- Patricio Riva‐Posse (ORCID: https://orcid.org/0000-0002-5887-0557)
- Binith Cheeran (ORCID: https://orcid.org/0000-0002-3442-1044)
- Lyndahl M. Himes (ORCID: https://orcid.org/0000-0001-5759-280X)
- Jip de Bruin (ORCID: https://orcid.org/0009-0003-1658-0986)
- Andres M. Lozano (ORCID: https://orcid.org/0000-0001-8257-3694)
- Ki Sueng Choi
Institutions
- Rutgers, The State University of New Jersey (US)
- University Health Network (CA)
- Emory University (US)
- University of Toronto (CA)
- Ontario Brain Institute (CA)
- International Neuromodulation Society (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- American Journal of Psychiatry
- Published
- 2026-10-01
- DOI
- https://doi.org/10.1176/appi.ajp.20250449
- Citations
- 1
- Primary Topic
- Neurological disorders and treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.88